Baxter/VimRx.
This article was originally published in The Gray Sheet
Executive Summary
Cell therapy joint venture, Nexell Therapeutics, will be headed by William McIntosh, former executive vice president of business development and chief financial officer at VimRx. Nexell, which formerly was Baxter's Immunotherapy Division, is developing and marketing cell therapies for cancer and other life-threatening diseases. The firm's lead products are the Isolex 300 and Isolex 300I cell selection systems. Although FDA's Biological Response Modifiers Advisory Committee did not take a formal vote on the Isolex 300's premarket approval application, the panel did agree that study data demonstrated efficacy ("The Gray Sheet" July 28, 1997, p. 8)...